Genetically Shared Signatures Between COVID-19 and Cancer Identified Through In Silico Case–Control Analysis
Genes · 2026
DOI: 10.3390/genes17020150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2026. Verfasst von Ammar Yasir Ahmed Ahmed und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, University of Al Maarif, Al Anbar P.O. Box 55431, Iraq. Hauptthemen laut MEDLINE: COVID-19, Triple Negative Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Cancer patients are highly susceptible to infectious diseases due to malignancy- and treatment-induced immunosuppression. The coronavirus disease 2019 (COVID-19) pandemic highlighted this vulnerability, particularly in aggressive tumors such as triple-negative breast cancer (TNBC) and clear cell renal cell carcinoma (ccRCC). However, the molecular mechanisms linking cancer progression with COVID-19 severity remain poorly defined. This study aimed to identify shared molecular signatures between COVID-19 and TNBC, breast cancer, and ccRCC using integrative bioinformatics approaches.
Methods
A comprehensive in silico case–control analysis was conducted using publicly available GEO transcriptomic datasets (GSE164805, GSE139038, GSE45498, and GSE105261). Differentially expressed genes (DEGs) were identified by comparing mild and severe COVID-19 cases with each cancer type. Protein–protein interaction (PPI) networks were constructed to identify hub genes, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Regulatory networks involving microRNAs (miRNAs) and transcription factors (TFs) were also examined.
Results
Shared hub genes were identified across COVID-19 and cancer datasets, including IGF1, MMP9, and NOTCH1 in TNBC; TOP2A, PXN, and CCNB1 in breast cancer; and ASPM and TTK in ccRCC. These genes are linked to immune regulation, inflammation, cell cycle control, and tumor progression. Enrichment analyses revealed convergent pathways such as MAPK signaling, cytokine–cytokine receptor interaction, Ras signaling, and proteoglycans in cancer. Key regulatory molecules, including miR-145-5p, miR-192-5p, miR-335-5p, and transcription factors NFKB1, BRCA1, and TP53, modulated both viral and oncogenic processes. Severe COVID-19 was associated with enhanced inflammatory and proliferation-related signaling across all cancer types.
Conclusions
This integrative, severity-stratified analysis identifies shared molecular and regulatory features linking severe COVID-19 with aggressive cancers, highlighting persistent immune activation and altered immune communication as common underlying themes without implying causality or clinical outcome effects. These findings provide a systems-level, hypothesis-generating framework for understanding virus–cancer interactions and may inform future biomarker discovery and immune-focused therapeutic strategies in vulnerable cancer populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, University of Al Maarif, Al Anbar P.O. Box 55431, Iraq.
- Department of Molecular Biology and Genetics, Faculty of Science and Arts, Kırşehir Ahi Evran University, Kırşehir 40100, Türkiye.
ORCID-Profile: Sevinç Akçay
Zitieren
APA
Ahmed, A. Y. A., & Akçay, S. (2026). Genetically Shared Signatures Between COVID-19 and Cancer Identified Through In Silico Case–Control Analysis. Genes. https://doi.org/10.3390/genes17020150
Vancouver
Ahmed AYA, Akçay S. Genetically Shared Signatures Between COVID-19 and Cancer Identified Through In Silico Case–Control Analysis. Genes. 2026. doi:10.3390/genes17020150
BibTeX
@article{Ahmed2026,
author = {Ahmed, Ammar Yasir Ahmed and Akçay, Sevinç},
title = {Genetically Shared Signatures Between COVID-19 and Cancer Identified Through In Silico Case–Control Analysis},
journal = {Genes},
year = {2026},
doi = {10.3390/genes17020150}
}
EUVIMED